PBAC's latest decision on Budesonide with glycopyrronium and formoterol: Recommended (2022). Considered for Long-term maintenance treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated by a combination of an inhaled corticosteroid (ICS) with a long-acting beta2-agonist (LABA), or LABA with a long-acting muscarinic antagonist (LAMA).
PBAC outcome
Recommended
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2022
Submissions
1
2022 → 2022
Eligible population
Patients with COPD not adequately treated by a combination of ICS with LABA, or LABA with LAMA
Therapy area
Respiratory
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
existing Breztri Aerosphere inhaler (cost-minimisation to lowest cost alternative agent including any combination of LAMA, LABA and corticosteroid)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis only; no ICER calculated as this is a device formulation change with equivalent active ingredients.
Risk sharing
Risk-sharing arrangement in place — Breztri Aerosphere subject to Deed of Agreement with expenditure caps; DFP-EvoCap would be subject to same arrangements.